• About us

    With a presence amongst the top 10 global veterinary pharmaceutical laboratories, Vetoquinol is first and foremost an independent, family-owned business.Deeply committed to its values, it has always enjoyed a close relationship with its vet clients.

  • Working at Vetoquinol


  • Achieve More Together

    Building trustworthy relationships with all stakeholders in animal health across the globe.

Vetoquinol live

  • 2019 SALES: €396.0 MILLION (UP 7.6%)

    23 Jan 2020
    The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates.      
  • Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement

    13 Dec 2019
    December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China. Through this agreement, Vetoquinol will develop and commercialize Klox’s fluorescent light energy (FLE) products in animal health.      
  • Q3 2019 SALES: €100.2 MILLION (UP 11.0%)

    16 Oct 2019
    The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year. Exchange rate fluctuations and acquisitions had positive impacts of 1.6% and 4.1% respectively in Q3 2019.

    25 Jul 2019
    At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements.
  • 23 january 2020

    2019 Annual revenues (after market)

  • 16 april 2020

    2020 First quarter revenues (after market)

  • 26 March 2020

    2019 Annual results (before market)


Find the nearest Vetoquinol contact point by selecting a country website